KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on Outcome
- 1 October 2010
- journal article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 33 (5) , 456-460
Abstract
KRAS mutated colorectal cancers (CRC) are reported to be associated with a poor response to anti-EGFR monoclonal antibody therapy and poor prognosis. We studied the rates of KRAS mutated tumors in patients with peritoneal carcinomatosis from CRC and investigated the association of KRAS status with specific clinicopathologic factors. A retrospective observational study of tumor specimens from 23 patients with peritoneal carcinomatosis from CRC was performed using standard genomic DNA sampling techniques to identify KRAS mutations. Correlation between clinicopathologic factors and KRAS mutation status was performed using the Fisher exact test or χ test, as appropriate. Eleven (48%) of 23 patients had KRAS mutations. There were no statistically significant correlations in patient demographics, tumor pathology, surgical evaluation, treatments, or survival outcomes for peritoneal carcinomatosis between patients with KRAS mutations or wild-type KRAS status. The prevalence of KRAS mutation in CRC patients with peritoneal carcinomatosis is 48% in this preliminary study and clinicopathologic factors appear to be independent of mutation status.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosisJournal of Surgical Oncology, 2008
- KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experienceJournal of Clinical Oncology, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinomaGut, 2005
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001
- K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal CancerJournal of Clinical Oncology, 2001
- Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" StudyJNCI: Journal of the National Cancer Institute, 1998
- Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.Proceedings of the National Academy of Sciences, 1989
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988
- Detection of high incidence of K-ras oncogenes during human colon tumorigenesisNature, 1987